As a new association prepares to advocate on Capitol Hill for medical use of psychedelics, experts say regulations on the drugs will likely remain the same under President-elect Donald Trump, and in contrast to comments made by Trump’s pick to lead HHS, Robert F. Kennedy Jr., the biggest barrier to the treatments is the U.S. Drug Enforcement Administration (DEA) not FDA. The Association for Prescription Psychedelics (APP) launched in November and said in a news release it plans to push...